Loading...
•
Dec 31, 2022
ORIC Pharmaceuticals Q4 2022 Earnings Report
Reported financial results and operational updates.
Key Takeaways
ORIC Pharmaceuticals reported its fourth quarter and full year 2022 financial results, highlighting progress across its clinical pipeline and a $25 million equity investment from Pfizer. The company anticipates initial Phase 1b data for three ongoing clinical trials in the second half of 2023 and expects its cash and investments to fund operations into the first half of 2025.
Initial Phase 1b data for ORIC-533, ORIC-114, and ORIC-944 expected in the second half of 2023.
Received $25 million equity investment from Pfizer.
Established clinical development collaboration with Pfizer for a potential Phase 2 study of ORIC-533 in combination with elranatamab in multiple myeloma.
Cash and investments of $228.2 million expected to fund operating plan into first half of 2025.
Forward Guidance
ORIC anticipates reporting initial safety, PK/PD, and preliminary antitumor activity data from ongoing single agent Phase 1b studies in the second half of 2023 for ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers and ORIC-944 in prostate cancer.
Positive Outlook
- Report initial safety data from ORIC-533 Phase 1b study in multiple myeloma in the second half of 2023.
- Report initial PK/PD data from ORIC-533 Phase 1b study in multiple myeloma in the second half of 2023.
- Report preliminary antitumor activity data from ORIC-533 Phase 1b study in multiple myeloma in the second half of 2023.
- Report initial safety, PK/PD, and preliminary antitumor activity data from ORIC-114 Phase 1b study in EGFR/HER2-mutated cancers in the second half of 2023.
- Report initial safety, PK/PD, and preliminary antitumor activity data from ORIC-944 Phase 1b study in prostate cancer in the second half of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...